Our system is currently under heavy load due to increased usage. We're actively working on upgrades to improve performance. Thank you for your patience.
2014
DOI: 10.1016/j.dsr2.2012.08.001
|View full text |Cite
|
Sign up to set email alerts
|

Paralytic shellfish toxins in clinical matrices: Extension of AOAC official method 2005.06 to human urine and serum and application to a 2007 case study in Maine

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
20
0

Year Published

2014
2014
2023
2023

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 24 publications
(20 citation statements)
references
References 18 publications
0
20
0
Order By: Relevance
“…in water samples that also test positive for DA with the ASP Jellett Rapid Testing kit. Most offshore U.S. waters, including Georges Bank, fall under federal jurisdiction and are managed by the U.S. Food and Drug Administration, primarily for PSP toxins at this time (DeGrasse et al, this issue). Other states, including those along the U.S. west coast where DA closures occur regularly (Lewitus et al, 2012; Trainer et al, 2009a; Trainer et al, 2009b), conduct routine shellfish flesh testing for DA.…”
Section: Introductionmentioning
confidence: 99%
“…in water samples that also test positive for DA with the ASP Jellett Rapid Testing kit. Most offshore U.S. waters, including Georges Bank, fall under federal jurisdiction and are managed by the U.S. Food and Drug Administration, primarily for PSP toxins at this time (DeGrasse et al, this issue). Other states, including those along the U.S. west coast where DA closures occur regularly (Lewitus et al, 2012; Trainer et al, 2009a; Trainer et al, 2009b), conduct routine shellfish flesh testing for DA.…”
Section: Introductionmentioning
confidence: 99%
“…To our knowledge, this is the first validated method for quantitation of STX in whole blood. When compared with analytical methods for detection of STX in other clinical matrices, this method is approximately 50 times more sensitive in whole blood and more than an order of magnitude more sensitive in dried blood than currently developed LC/MS-MS methods for quantitation of STX in urine and approximately 200 times more sensitive in whole blood and 66 times more sensitive in dried blood than previously reported LC-MS methods for serum (Bragg et al, 2015; DeGrasse et al, 2014; Johnson et al, 2009). Because of this method’s high sensitivity compared with other techniques, it would be advantageous to add as a screening measure of PSP exposures so as not to report out false negatives.…”
Section: Discussionmentioning
confidence: 92%
“…There is currently very little published data on STX levels in clinical specimens. Two reports of STX exposures identified STX levels of up to 51 nM (15.3 ng/mL) in serum and 3.4 μM (1017 ng/mL) in urine during acute exposure (DeGrasse et al, 2014; Gessner et al, 1997). Because onset of symptoms occur quickly (within 1–2 h of exposure) and the half-life of STX is short (less than 10 h in serum and 20.4 h in urine), it is important to develop methods that are rapid, accurate, and sensitive to detect STX in clinical samples and confirm diagnosis.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Along this line, recently the official pre-column method (AOAC 2005.06) was extended to human urine and serum [80]. The complexity of clinical matrices and the current lack of standard operating procedures for clinical samples, however, make the identification and quantification of the PSP toxins rather difficult.…”
Section: Review and Discussion Of Trends In Analytical Methods For Bimentioning
confidence: 98%